Serum quinidine concentrations were determined in patients on chronic therapeutic doses. Although results were higher by a protein precipitate-fluorescence method as compared to a specific extraction fluorescence method, there was substantial correlation between results by the two methods (r = 0.945, P < 0.00 1). We established the specificity of the extraction method by a methylation gas-chromtographic method and by a gas-chromatographic/mass spectrometric method in which the base peak in the mass spectra of the methylated products of both quinidine and cinchonidine, the internal standard, was monitored.
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Serum quinidine concentrations were determined in patients on chronic therapeutic doses. Although results were higher by a protein precipitate-fluorescence method as compared to a specific extraction fluorescence method, there was substantial correlation between results by the two methods (r = 0.945, P < 0.00 1). We established the specificity of the extraction method by a methylation gas-chromtographic method and by a gas-chromatographic/mass spectrometric method in which the base peak in the mass spectra of the methylated products of both quinidine and cinchonidine, the internal standard, was monitored.
We cOnclude that the protein precipitate method should be discarded.
AdditionalKeyphrase: cardiac arrythmias
Knowledge of serum quinidine concentrations assists the physician in the management of patients who are receiving quinidine (1) (2) (3) (4) which benzene is used as the organic solvent. In a further modification of this method, Kessler et al. (9) studied the pharmacokinetics of quinidine in patients with renal failure and congestive heart failure, and recommeided that the protein-precipitate method be abandoned in favor of the more specific extraction method.
We have determined quinidine concentrations in the sera of 27 patients who were receiving quinidine sulfate as therapy for cardiac arrhythmias.
This report compares the quinidine concentrations determined by the two fluorescence methods with those by a specific gaschromatographic method (10) , the validity of which we have confirmed by gas chromatography/mass spec-
trometry (GC/MS).

Materials and Methods
Patients
All patients were hospitalized on a general medical service and had been receiving quinidine sulfate for at least three days. Blood for quinidine concentration was obtained by venipuncture 4-6 h after the last oral dose of quinidine sulfate. The blood was centrifuged, and the serum was either promptly assayed or frozen at -20 #{176}C until assay. Creatinine clearances for the patients were either measured or were estimated with use of a nomogram involving the patient's serum creatinine value, age, sex, and weight (11).
Fluorescence Assays
Fluorescence method I was the protein precipitate method described by Brodie and Udenfriend For both methods fluorescence was measured in a Farrand spectrophotofluorometer (activation wavelength, 350 nm; fluorescence wavelength, 445 nm) and compared with quinidine standards that had been carried through the entire procedure.
All quinidine concentrations are given in micrograms of quinidine base per milliliter of serum.
Gas Chromatography
We used a modification of the flash methylation procedure of Midha and Charette (10) . To duplicate 1-ml serum samples, 1 ml of water containing the internal standard, cinchonidine (2 sg/ml), 0.5 ml of NaOH (1 mol/liter), and 5 ml of benzene were added. The mixture was shaken for 10 mm, centrifuged, and the benzene layer transferred to a conical tube and evaporated at 70 #{176}C under air. The residue was reconstituted The column was a 180-cm glass column packed with 3%
OV-17 on Gas Chrom Q, 80-100 mesh. The temperatures of the injection port, column, and detector were 320, 245, and 285 #{176}C, respectively.
Under these conditions the retention times for methylated cinchonidine and quinidine were 4.25 and 7.2 mm, respectively. There were no interfering peaks in blank plasma carried through the entire procedure, but two later-eluting peaks were present in the blank plasma. The sensitivity limit for serum quinidine concentration was 50 ng/ml. Quinidine concentrations were determined by the peak-height ratio for quinidine and the internal standard. Four quinidine standards (1, 3, 5, and 7 tg/ml) were prepared in blank plasma and assayed together with the patient's sera. Because quinidine sulfate was used to prepare the standards, it was necessary to multiply the determined quinidine concentrations by 0.82, to obtain the quinidine concentrations as micrograms of quinidine base per milliliter of serum. The coefficient of variation for 10 determinations on the same day was 4.7%.
Gas Chromatography/Mass Spectrometry
To substantiate the results determined by GC analysis, portions of selected samples were also analyzed by GC/MS. The GC/MS computer system was the Finnigan 3300, operated on line with a Finnigan 6000 data system. The electron impact mass spectra were continuously monitored throughout the complete temperature-programmed gas chromatographic analysis, 5-10 mass spectra being recorded for each effluent Fig. 3 . Mass chromatograms for m/e 136, the base peak in the mass spectra of the methylated products of both quinidine (Q) and cinchonidine (IS) for a 5 tg/ml quinidine standard (panel A), and two patients (panels B and C) Column conditions identical to the GC analyses except that helium was the carrier gas (30 mI/mm) and the column temperature was programmed from 220 to 320 #{176}C at 10 #{176}C/min component.
The mass chromatogram for m/e 136, the base peak in the mass spectra of the methylated products of both quinidine and cinchonidine (10) was used to determine the concentration of quinidine in each sample. The computer system was used to determine the areas of the peaks in the mass chromatogram for both quinidine and internal standard. The ratio of the areas of the two peaks in the unknown sample was then compared to the area ratio for a standard sample containing known amounts of quinidine and internal standard, carried through the same procedure.
Results and Discussion
In agreement with earlier reports (1, (7) (8) (9) , quinidine concentrations as determined by the protein precipitate method (fluorescence method I) are higher than those determined by the extraction method. Despite these differences there was a substantial correlation ( Figure   1 ) between results by the two methods (r = 0.945, P < 0.001). To determine which method was the more nearly accurate, the same serum samples were assayed by the GC method. As demonstrated in Figure 2 , there was an excellent correlation between results by gas chromatography and by fluorescence method II (r = 0.959, P <0.001), which indicated that the extraction method was more specific than the protein precipitate method.
To further substantiate the accuracy and specificity of the second fluorescence method, we used the GC/MS system. Methylated quinidine and cinchonidine both have base peaks at mle 136, and so we could use a single mass chromatogram for quantitation.
The correct peaks for each compound in the mass chromatogram were chosen on the basis of both retention times and examination of the complete mass spectra. Figure 3 shows three such mass chromatograms.
The areas of the peaks corresponding to quinidine and the internal standard were determined with the aid of the computer. From these data, we conclude that the extraction fluorescence method (II) is both accurate and specific and should therefore be used when the pharmacokinetics of quinidine are to be studied. However, under certain circumstances, the protein precipitate method may be preferred for monitoring clinical response to quinidine in patients: it is easier than the extraction method and, after the initial protein precipitation step, could be done by an automated procedure.
However, if the protein precipitate method is used, the resulting quinidine concentrations should be divided by two to obtain an estimate of the actual quinidine concentration.
An objection to using the protein precipitation method was raised by Kessler et al. (9) . They determined the ratio of quinidine concentrations determined by the two methods (I/Il), related this ratio to the renal function of that patient, and found a significant inverse correlation between these variables. That is, as creatinine clearance decreased, the ratio (I/Il) increased. They interpreted this to indicate a greater retention of the water-soluble metabolites of quinidine and dihydroquinidine relative to quinidine in renal failure. The varying amounts of these metabolites changed the ratio of the quinidine concentrations determined by the two methods, and this was the basis of their recommendation that the protein precipitate method be discarded.
In our experience, however, this relationship was not as evident. The mean (±SD) ratio for quinidine concentration determined by the two methods (I/Il) was 2.0 ± 0.29 (range, 1.55 to 2.54). The endogenous creatmine clearances of these patients varied from 15 to 85 ml/min, and there was no correlation between the ratio and creatinine clearance.
It is possible, however, that an increased ratio (I/Il) might occur in patients with more severe renal-function impairment. Because results of the fluorescence method II agree well with those of GC and GC/MS methods, and because fluorescence method I gives quinidine concentrations that average twice those obtained by fluorescence method II, then fluorescence method I, the protein precipitate method, gives erroneous results and should be discarded.
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